Fulgent Genetics shares fell 7.0% post-earnings as investors reacted to a notable sequential revenue decline and soft performance in the laboratory services segment, driven by the loss of a major customer. While management reiterated full-year revenue guidance and highlighted progress in therapeutic development, the quarter's deceleration and updated EPS guidance disappointed expectations.

• Q1 revenue came in at $71.1 million, representing a 3.2% year-over-year decrease and a sharper 14.6% decline sequentially, with the drop primarily attributed to a large customer insourcing testing.
• Management maintained full-year 2026 revenue guidance but adjusted non-GAAP EPS and cash balance outlook due to share repurchases.
• The laboratory service business struggled this quarter despite recent acquisitions (Bako Diagnostics and StrataDx), underscoring segment-specific pressures.
• Therapeutic development advanced, with FID-007 enrollment for Phase II trial completed on schedule and a Phase III program targeted for 2027.
• Management continues to point to AI and digital pathology investments as long-term growth drivers, though near-term headwinds weighed on the quarter’s results.